Libera Bio — Seed · €289.5K

XesGalicia, through its Galicia InnovaTech fund, invested €289,500 in a capital increase at Libera Bio, a University of Santiago de Compostela spin-off developing nanoparticle-delivered antibody therapies for cancer (MPN Technology). The total size of the round was not disclosed at announcement; XesGalicia joined alongside family office Rosp Corunna Participaciones Empresariales and a private investor, following venture builder Nowture's earlier entry.